ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brainAristeidis Lentzas, Olaf van Tellingen, Jos H. Beijnen et al.|Fluids and Barriers of the CNS|2024Cited by 9
P10.21.A THE ABCB1/ABCG2 INHIBITOR ELACRIDAR IS A MORE POTENT PHARMACOENHANCER COMPARED TO TARIQUIDAR FOR TREATMENT OF INTRACRANIAL TUMORS WITH SMALL MOLECULE DRUGSAristeidis Lentzas, Olaf van Tellingen, Mark C. de Gooijer et al.|Neuro-Oncology|2023Cited by 1
EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIEROlaf van Tellingen, Jos H. Beijnen, Nikkie Venekamp et al.|Neuro-Oncology|2020Cited by 0